An interventional study of Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT) in Moderate Aortic Valve Stenosis, sponsored by Medtronic Cardiovascular. Active, not recruiting at 94 sites in 16 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Medtronic Cardiovascular (part of Medtronic) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 116 studies in Constriction, Pathologic with a site in United States — 14 open to participants now, 18 under way, 2 of them phase 3. Constriction, Pathologic · United States.
Among the 116 studies in Constriction, Pathologic with a site in United States, this one is the 6th largest by planned enrollment of the 82 interventional ones that give a count, is one of 6 that started in 2022, is one of 53 with no phase, reaches primary completion later than 10 of the 17 other live ones, and was the 93rd registered.
457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.
Browse Constriction, Pathologic studies →14 of the 116 studies in Constriction, Pathologic with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Medical College of Wisconsin · Sites in United States
Ages 18+
Urotronic Inc. · Sites in United States
Ages 18+
Children's Hospital Los Angeles · Sites in United States
Ages 12–21
NYU Langone Health · Sites in United States
Ages 48+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
116 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 12 · Phase 3 6 · Phase 4 9
First in 2000; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 650 is above the median of 72 across 296 interventional studies indexed under Constriction, Pathologic.
Median enrollment 40 across the 82 interventional studies, 62 across the 32 observational. Of the 82 that completed or were terminated, 40 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 116 have an industry lead sponsor. The 10 most frequent:
This study is registered under Medtronic Cardiovascular, one of the names counted as Medtronic. Under that name alone:
Medtronic Cardiovascular is the lead sponsor of 64 studies on the registry; 7 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Medtronic has 2 studies filed under Constriction, Pathologic — fewer than ten, so there is no comparison to draw.
8 of the studies in Constriction, Pathologic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07456137University of Kansas Medical CenterProspective Evaluation of Upright Versus Supine CT Myelography of the Lumbar Spine | 2026-12 |
| NCT05691062Twin Cities Spine CenterTitanium vs. PEEK Fusion Devices in 1 Level TLIF | 2027-01-11 |
| NCT06410313Medinol Ltd.First In Human Study to Assess Safety and Efficacy of the ChampioNIR™ Drug Eluting Peripheral Stent in the Treatment of Patients With Superficial Femoral Artery Disease and/or Proximal Popliteal Artery Disease | 2027-01-30 |
| NCT07020520Urotronic Inc.EvaluatioN of Optilume Drug-Coated Balloon for the Endoscopic Treatment of UREteric Strictures | 2027-02-28 |
| NCT05779436Mayo ClinicReal-Time Cholangioscopy Artificial Intelligence Evaluation of Biliary Strictures | 2027-03 |
Add all 8 to your calendar (.ics) → With an account.
Among the 116 studies in Constriction, Pathologic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Multi-center, international, prospective, randomized study. Subjects will be randomized to either transcatheter aortic valve replacement (TAVR) with the Evolut PRO+ TAVR System, or Evolut FX System, and guideline-directed management (GDMT) or GDMT alone.
Key Inclusion Criteria:
o Moderate AS, defined as follows by transthoracic echo (TTE) as assessed by the ECL:
and
Any of the following at-risk features:
Reduced functional capacity, defined as
Any of the following by the qualifying TTE as assessed by the ECL:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Medtronic Evolut PRO+ TAVR or Evolut FX TAVR Systems, \& guideline-directed management \& therapy
Device: Medtronic Evolut PRO+ TAVR System, or Evolut FX TAVR System, and guideline-directed management and therapy (GDMT)
Clinical site determined guideline-directed management and therapy (GDMT) alone
Patients will have a Transcatheter Aortic Valve Replacement (TAVR) with either an Evolut PRO+ TAVR, or Evolut FX TAVR, heart valve, and given clinical site-determined guideline-directed management and therapy (GDMT).
Composite rate of all-cause mortality, all-stroke, life threatening or fatal bleeding, acute kidney injury, hospitalization due to device or procedure-related complication, or valve dysfunction requiring reintervention.
Life threatening or fatal bleeding is defined as BARC Type 3 or 4 and acute kidney injury is defined as VARC-3 Stage IV.
Time frame: 30 days
Composite rate of all-cause mortality, heart failure hospitalization or event, or medical instability leading to aortic valve replacement or re-intervention.
Time frame: 2 years
Proportion of subjects alive and with moderately improved quality of life (≥ 10 points in KCCQ summary score from baseline)
Time frame: 1 year
Composite of all-cause mortality and heart failure hospitalizations or events.
Time frame: 2 years
Composite of all-cause mortality, all-stroke, or unplanned CV hospitalizations
Time frame: 2 years
Heart failure hospitalizations or events.
Time frame: 2 years
All-cause mortality
Time frame: 2 years
Unplanned cardiovascular hospitalizations
Time frame: 2 years
Days alive and free of unplanned cardiovascular hospitalizations
Time frame: 2 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2022 (actual). Primary completion is estimated for Sep 2027, 65 months after the start.
Of 43 industry-sponsored interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 58. This study's planned 65 months is above that.
Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.